Scientific studies, publications and articles on oncologic drugs for the treatment of patients.


ReceptaBio Works

Conference Presentations

Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR).

Smaletz O, Ismael G, Diz MDPE, Nascimento IL, Wiermann ALG, Cunha GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, dos Santos ML, Majumder I, Hoffman EW. Journal of Clinical Oncology 2017 35:15_suppl, e17039-e17039.

Humanized anti-NaPi2b Monoclonal Antibody-Cell Line Generation.

Yeda FP, Santos, ML, Tsuruta LR, Horta, BB, Pimenta Jr. AA, Ritter, G, Moro, AM.

Generation of a Stable Cell Line for Rebmab200 MAb.

Santos ML, Yeda, FP, Tsuruta LR, Horta, BB, Pimenta Jr. AA, Ritter, G, MORO, AM. p. 67.

Lewis B (LeB) antigen expression is lower in breast carcinoma and is associated with hormone receptor status and histological type.

Simões K, Soares IC, Wakamatsu A, Okamoto OK, Alves VAF. Clinics 2010,65 (supl 6): S54 – 46.

Stability analysis of humanized Rebmab100 monoclonal antibody.

Santos ML, Pimenta Jr. AA, Pavanelli AC, Schmidt MCB, Old LJ, Smaletz O, Moro AM. Abstract book, p. 163.

Flow Cytometry Characterization of Rebmab200.

Santos ML, Pavanelli AC, Degaki TL, Inocêncio AL, Tsuruta LR, Travassos LRR, Old LJ, Ritter G, Moro AM. Abstract book, p. 129.

Generation of Humanized Rebmab200.

Degaki TL, Pimenta Jr. AA, Tsuruta LR, Targino RC, Old LJ, Ritter G, Okamoto OK, Moro AM. Abstract book, p.133.